[Form 4] Twist Bioscience Corp Insider Trading Activity

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported a new equity award to its Chief Executive Officer and director, Emily M. Leproust. On 11/18/2025, she received 146,914 shares of common stock in the form of restricted stock units at a reported price of $0 per share, increasing her directly held beneficial ownership to 880,836 common shares.

The RSU grant vests over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to continued service. The filing also lists multiple outstanding employee stock options, including options with exercise prices of $8.82, $26.66, $23.33, and $67.85, covering hundreds of thousands of shares with expiration dates between 2027 and 2030. Some older options at $5.95 now show zero remaining shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leproust Emily M.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		A		146,914(1)	A	$0	880,836	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.95							(2)	09/28/2025	Common Stock	0		0	D
Employee Stock Option (right to buy)	$8.82							(3)	09/28/2027	Common Stock	0		150,879	D
Employee Stock Option (right to buy)	$26.66							(4)	11/18/2028	Common Stock	0		266,539	D
Employee Stock Option (right to buy)	$23.33							(5)	10/23/2029	Common Stock	0		131,290	D
Employee Stock Option (right to buy)	$67.85							12/19/2022	08/31/2030	Common Stock	64,950		64,950(6)	D

Explanation of Responses:

1. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.

2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

4. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

5. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

6. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Twist Bioscience (TWST) report in this Form 4 filing?

The filing reports that CEO and director Emily M. Leproust received 146,914 restricted stock units (RSUs) of Twist Bioscience common stock on 11/18/2025, increasing her directly held beneficial ownership to 880,836 shares.

How do the new RSUs for Twist Bioscience CEO Emily Leproust vest?

The 146,914 RSUs vest over a total period of 48 months. 1/16 of the RSUs vest on each quarterly anniversary of November 20, 2025, subject to her continuous service through each vesting date.

What is the reported acquisition price of the new Twist Bioscience RSUs?

The RSU award to Emily Leproust is reported at a price of $0 per share, which is typical for restricted stock units granted as part of equity compensation rather than purchased in the market.

How many Twist Bioscience shares does Emily Leproust beneficially own after this transaction?

Following the reported RSU grant, Emily Leproust is shown as beneficially owning 880,836 shares of Twist Bioscience common stock in direct ownership.

What stock options for Twist Bioscience does Emily Leproust hold according to this filing?

The filing lists several employee stock options, including options with exercise prices of $8.82, $26.66, $23.33, and $67.85. These options relate to underlying common stock and have expiration dates ranging from 09/28/2027 to 08/31/2030, with remaining amounts such as 150,879, 266,539, 131,290, and 64,950 options shown as beneficially owned.

What are the performance stock options mentioned for Twist Bioscience’s CEO?

The filing notes a grant of performance stock options awarded on September 1, 2020, which vested and became exercisable on December 19, 2022 after Emily Leproust met the applicable performance criteria. These are shown as 64,950 options with an exercise price of $67.85 and an expiration date of 08/31/2030.